β-Secretases, Alzheimer's Disease, and Down Syndrome

Individuals with Down Syndrome (DS), or trisomy 21, develop Alzheimer's disease (AD) pathology by approximately 40 years of age. Chromosome 21 harbors several genes implicated in AD, including the amyloid precursor protein and one homologue of the β-site APP cleaving enzyme, BACE2. Processing of the amyloid precursor protein by β-secretase (BACE) is the rate-limiting step in the production of the pathogenic Aβ peptide. Increased amounts of APP in the DS brain result in increased amounts of Aβ and extracellular plaque formation beginning early in life. BACE dysregulation potentially represents an overlapping biological mechanism with sporadic AD and a common therapeutic target. As the lifespan for those with DS continues to increase, age-related concerns such as obesity, depression, and AD are of growing concern. The ability to prevent or delay the progression of neurodegenerative diseases will promote healthy aging and improve quality of life for those with DS.

[1]  L. Hersh,et al.  BACE2 expression increases in human neurodegenerative disease. , 2012, The American journal of pathology.

[2]  Brian J Cummings,et al.  Diffuse plaques contain C-terminal Aβ 42 and not Aβ 40: Evidence from cats and dogs , 1996, Neurobiology of Aging.

[3]  Lora J. H. Bean,et al.  Epidemiology of Down syndrome. , 2007, Mental retardation and developmental disabilities research reviews.

[4]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[5]  M. Dierssen,et al.  Protein expression of BACE1, BACE2 and APP in Down syndrome brains , 2008, Amino Acids.

[6]  J. Lejeune,et al.  [Study of somatic chromosomes from 9 mongoloid children]. , 1959, Comptes rendus hebdomadaires des seances de l'Academie des sciences.

[7]  Filippo Caraci,et al.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. , 2012, British journal of clinical pharmacology.

[8]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[9]  G. Koelsch,et al.  Human aspartic protease memapsin 2 cleaves the b-secretase site of b-amyloid precursor protein , 2000 .

[10]  H. Mori,et al.  Increased Aβ 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene , 1997, Neuroscience Letters.

[11]  J. Stockley,et al.  The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. , 2007, Biochemical Society transactions.

[12]  K. Gardiner,et al.  The proteins of human chromosome 21 , 2006, American journal of medical genetics. Part C, Seminars in medical genetics.

[13]  J. Smyth,et al.  Progress in Clinical and Biological Research , 1979 .

[14]  R. Nieuwenhuis-Mark.  Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. , 2009, Research in developmental disabilities.

[15]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Rasmussen,et al.  Setting a public health research agenda for Down syndrome: Summary of a meeting sponsored by the Centers for Disease Control and Prevention and the National Down Syndrome Society , 2008, American journal of medical genetics. Part A.

[17]  F. Schmitt,et al.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[18]  S. Love,et al.  Accumulation of insoluble amyloid-β in down's syndrome is associated with increased BACE-1 and neprilysin activities. , 2011, Journal of Alzheimer's disease : JAD.

[19]  G. Westmeyer,et al.  A non‐amyloidogenic function of BACE‐2 in the secretory pathway , 2002, Journal of neurochemistry.

[20]  D. Selkoe,et al.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. , 1994, The Journal of biological chemistry.

[21]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[22]  Alison Abbott,et al.  Dementia: A problem for our age , 2011, Nature.

[23]  D. Selkoe,et al.  Intraneuronal Aβ42 accumulation in Down syndrome brain , 2002 .

[24]  David M Holtzman,et al.  Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-β Peptide, Partial Restoration via γ-Secretase Inhibition , 2008, The Journal of Neuroscience.

[25]  G. Perry,et al.  Striation is the characteristic neuritic abnormality in Alzheimer disease , 1998, Brain Research.

[26]  X. Estivill,et al.  A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer’s amyloid precursor protein β-secretase , 2000, Cytogenetic and Genome Research.

[27]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[28]  H. Lehrach,et al.  Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes , 2011, BMC Genomics.

[29]  C. Schnitzler,et al.  BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .

[30]  M. Gerstein,et al.  The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies , 2009, Proceedings of the National Academy of Sciences.

[31]  Kuo-Chen Chou,et al.  Prediction of the Tertiary Structure of the β-Secretase Zymogen☆ , 2002 .

[32]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[33]  C. Glabe,et al.  Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.

[34]  J. Trojanowski,et al.  Long-Term Accumulation of Amyloid-β, β-Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma , 2004 .

[35]  C. Dingwall,et al.  Prodomain Processing of Asp1 (BACE2) Is Autocatalytic* , 2001, The Journal of Biological Chemistry.

[36]  J. Haxby,et al.  Longitudinal study of neuropsychological function in older adults with Down syndrome. , 1992, Progress in clinical and biological research.

[37]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[38]  S. Freeman,et al.  Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects , 2009, Human Genetics.

[39]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[40]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[41]  J. Krischer,et al.  Down syndrome: national conference on patient registries, research databases, and biobanks. , 2011, Molecular genetics and metabolism.

[42]  B. Dickinson,et al.  S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors , 2011, PloS one.

[43]  Y. Lyubchenko,et al.  Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease , 2005, Neurological research.

[44]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[45]  X. Estivill,et al.  Characterization of a mouse model overexpressing beta‐site APP‐cleaving enzyme 2 reveals a new role for BACE2 , 2010, Genes, brain, and behavior.

[46]  S. Love,et al.  Changes with Age in the Activities of β‐Secretase and the Aβ‐Degrading Enzymes Neprilysin, Insulin‐Degrading Enzyme and Angiotensin‐Converting Enzyme , 2010, Brain pathology.

[47]  Kuo-Chen Chou,et al.  Insights from modeling the tertiary structure of human BACE2. , 2004, Journal of proteome research.

[48]  B. Tycko,et al.  Successful aging in a 70-year-old man with down syndrome: a case study. , 2008, Intellectual and developmental disabilities.

[49]  Xiulian Sun,et al.  BACE2, as a novel APP θ‐secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  Melissa J. Allman,et al.  Development and validation of the Arizona Cognitive Test Battery for Down syndrome , 2010, Journal of Neurodevelopmental Disorders.

[51]  B. Hyman,et al.  Beta-secretase activity increases with aging in human, monkey, and mouse brain. , 2004, The American journal of pathology.

[52]  M. Dierssen,et al.  In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model , 2010, Amino Acids.

[53]  S. Krinsky-McHale,et al.  Sequence of cognitive decline in dementia in adults with Down's syndrome. , 2000, Journal of intellectual disability research : JIDR.

[54]  D. Mann.  Neuropathology of Alzheimer’s disease in Down syndrome , 2018, Down Syndrome and Alzheimer’s Disease.

[55]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[56]  J. Hardy,et al.  A locus for familial early–onset Alzhelmer's disease on the long arm of chromosome 14, proximal to the α1–antichymotrypsin gene , 1992, Nature Genetics.

[57]  R. Doms,et al.  Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. , 2000, Molecular neurobiology.

[58]  K. Grzeschik,et al.  The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor , 1987 .

[59]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[60]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[61]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[62]  M. Murphy,et al.  BACE1 and BACE2 enzymatic activities in Alzheimer’s disease , 2010, Journal of neurochemistry.

[63]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[64]  Hans Lassmann,et al.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ , 2004, Acta Neuropathologica.

[65]  D. Selkoe,et al.  The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.

[66]  D. Selkoe,et al.  Normal and abnormal biology of the beta-amyloid precursor protein. , 1994, Annual review of neuroscience.

[67]  Jérôme Lejeune,et al.  Etude des chromosomes somatiques de neuf enfants mongoliens. , 1959 .

[68]  G. Binetti,et al.  BACE-2 is overexpressed in Down’s syndrome , 2003, Experimental Neurology.

[69]  E. Masliah,et al.  Synaptic and neuritic alterations during the progression of Alzheimer's disease , 1994, Neuroscience Letters.

[70]  A. Holland,et al.  Gene expression profiling in the adult Down syndrome brain. , 2007, Genomics.

[71]  D. Selkoe,et al.  The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a , 1996 .

[72]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[73]  C. Finch,et al.  Evidence for Apoptotic Cell Death in Alzheimer's Disease , 1995, Experimental Neurology.

[74]  J. Hardy,et al.  Amyloid precursor protein gene mutation in early-onset Alzheimer's disease , 1991, The Lancet.

[75]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[76]  T. Iwatsubo,et al.  Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). , 1996, Biochemical and biophysical research communications.

[77]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[78]  M. Kindy,et al.  Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. , 2012, Biochimica et biophysica acta.

[79]  G. Ransmayr,et al.  Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer’s disease β-secretase (BACE-1) , 2004, Journal of Neural Transmission.